BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: RelatlimabBiological: Nivolumab
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT05498480
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
- Conditions
- MelanomaUrothelial Carcinoma
- Interventions
- Drug: Nivolumab/rHuPH20
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05496192
- Locations
- 🇩🇪
Local Institution - 0001, Berlin, Germany
🇪🇸Local Institution - 0002, Sevilla, Spain
🇩🇪Local Institution - 0020, Essen, North Rhine-Westphalia, Germany
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- Conditions
- Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Non-mavacamten symptomatic oHCM therapy
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1600
- Registration Number
- NCT05489705
- Locations
- 🇺🇸
Alaska Heart Institute, Anchorage, Alaska, United States
🇺🇸Pima Heart and Vascular, Tucson, Arizona, United States
🇺🇸UAMS, Little Rock, Arkansas, United States
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 154
- Registration Number
- NCT05478499
- Locations
- 🇺🇸
Local Institution - 0001, Hot Springs, Arkansas, United States
🇺🇸Local Institution - 0007, Indianapolis, Indiana, United States
🇺🇸Local Institution - 0041, Louisville, Kentucky, United States
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT05469737
- Locations
- 🇺🇸
Local Institution - 0073, Pittsburgh, Pennsylvania, United States
🇭🇰Local Institution - 0180, Shatin, Hong Kong
🇯🇵Local Institution - 0154, Sapporo, Hokkaido, Japan
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT05470985
- Locations
- 🇺🇸
Local Institution - 0008, Seattle, Washington, United States
🇺🇸Local Institution - 0010, Garden Grove, California, United States
🇺🇸Local Institution - 0071, Lebanon, New Hampshire, United States
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05445440
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy
- Conditions
- Melanoma
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 95
- Registration Number
- NCT05432622
- Locations
- 🇺🇸
Local Institution, The Woodlands, Texas, United States
Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database
- Conditions
- Advanced Melanoma
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1008
- Registration Number
- NCT05426239
- Locations
- 🇩🇪
Site0001, Frankfurt, Germany
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
- Conditions
- Stem Cell Transplantation
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 378
- Registration Number
- NCT05421299
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States